Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,018 questions · 3,100 findings · 369 reviews · Headline outcomes only

No studies found 774 · 25%GRADE not reported 108 · 3.5%Very low 727 · 23.5%Low 840 · 27.1%Moderate 474 · 15.3%High 177 · 5.7%

Macrolides vs tetracycline

Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease

The review found no eligible studies for this question.

1 finding from 1 review

Macrolide+tetracycline vs macrolides

Number of people experiencing one or more exacerbations, Drug resistance/microbial sensitivity (as reported by trialists), including emergence of atypical bacteria, Number of participants colonised with Pseudomonas aeruginosa · patients with chronic obstructive pulmonary disease

The review found no eligible studies for this question.

1 finding from 1 review

Nonavalent HPV vaccine vs quadrivalent HPV vaccine

High‐grade cervical intraepithelial neoplasia, adenocarcinoma in situ, and cervical cancer · 9‐ to 26‐year‐old females and males

Nonavalent HPV vaccine showed no clear difference in high‐grade cervical intraepithelial neoplasia, adenocarcinoma in… compared with quadrivalent HPV vaccine (high certainty).

1 finding from 1 review

Inhaled corticosteroids vs placebo

Pseudomonas aeruginosa (P aeruginosa) colonisation · people with bronchiectasis

Inhaled corticosteroids showed no clear difference in pseudomonas aeruginosa (P aeruginosa) colonisation compared with placebo (low certainty).

1 finding from 1 review

Alpha2‐adrenergic agonist vs control

Hypotension (requiring treatment with inotropes or vasopressors during the period of study drug administration) · adults undergoing cardiac surgery

Alpha‐2 adrenergic agonists showed no clear difference in hypotension (requiring treatment with inotropes or vasopressors… compared with control (low certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist (VKA)

Minor bleeding · people with cancer with thrombosis prophylaxis and central venous catheters

It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes minor bleeding (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).

1 finding from 1 review